PRGO.TA - Perrigo Company plc

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
16,690.00
0.00 (0.00%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close16,690.00
Open17,030.00
Bid20,000.00 x 7100
Ask16,700.00 x 29700
Day's Range16,600.00 - 17,030.00
52 Week Range13,730.00 - 24,320.00
Volume76,483
Avg. Volume113,603
Market Cap22.849B
Beta (3Y Monthly)1.47
PE Ratio (TTM)9,236.30
EPS (TTM)1.81
Earnings DateN/A
Forward Dividend & Yield2.94 (1.76%)
Ex-Dividend Date2019-11-27
1y Target Est86.00
  • Perrigo to Present at the Morgan Stanley Global Consumer & Retail Conference
    PR Newswire

    Perrigo to Present at the Morgan Stanley Global Consumer & Retail Conference

    DUBLIN, Nov. 13, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at 10:00 AM EST on Wednesday, December 4, 2019. Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

  • Benzinga

    Witi, Perrigo Partner To Help Smokers Overcome Nicotine Addiction

    Witi, a producer of medical-grade vaporization devices, announced Thursday it has partnered with Perrigo (NYSE: PRGO) to create a new smoking cessation product. The two companies plan to work on an electronic nicotine delivery system that would later be submitted for approval by the FDA and other international regulatory agencies. Perrigo is a dominant figure in nicotine replacement therapy, with a plethora of products intended to help smokers quit.

  • Here's One Drugmaker That Popped On Earnings — And Two That Didn't
    Investor's Business Daily

    Here's One Drugmaker That Popped On Earnings — And Two That Didn't

    Shares of Ionis Pharma jumped Wednesday after the biotech's third-quarter sales and profit easily topped Wall Street's estimates. But Perrigo and Elanco stocks dipped after their reports.

  • GuruFocus.com

    US Stocks Retreat Wednesday

    CVS Health posts 3rd-quarter earnings beat Continue reading...

  • Perrigo Company plc Reports Third Quarter 2019 Financial Results
    PR Newswire

    Perrigo Company plc Reports Third Quarter 2019 Financial Results

    Continues Successful Transformation to a Consumer Self-Care Company Raises 2019 Adjusted EPS Guidance DUBLIN , Nov. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider ...

  • 3 Loyal Dividend Payers Declare Distributions
    GuruFocus.com

    3 Loyal Dividend Payers Declare Distributions

    Crawford & Company tops the list Continue reading...

  • Did You Manage To Avoid Perrigo's (NYSE:PRGO) Painful 65% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Perrigo's (NYSE:PRGO) Painful 65% Share Price Drop?

    Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...

  • Perrigo Announces Quarterly Dividend
    PR Newswire

    Perrigo Announces Quarterly Dividend

    DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21 per share, payable on December 17, 2019 to shareholders of record on November 29, 2019. Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-Care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

  • Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product
    PR Newswire

    Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product

    TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

  • Hedge Funds Are Betting On Perrigo Company plc (PRGO)
    Insider Monkey

    Hedge Funds Are Betting On Perrigo Company plc (PRGO)

    Is Perrigo Company plc (NYSE:PRGO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]

  • GuruFocus.com

    Jerome Dodson to Speak at 2020 GuruFocus Value Conference

    Founder and chairman of Parnassus Investments to make a speech at upcoming GuruFocus Value Conference Continue reading...

  • Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date
    PR Newswire

    Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date

    TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a conference call beginning at 8:00 a.m. (EDT).

  • Perrigo Company Upgraded to Buy
    Yahoo Finance

    Perrigo Company Upgraded to Buy

    This excerpt was brought to you by Argus Research using the Research Reports feature available through Yahoo Finance Premium. · Perrigo Company (PRGO), a longtime leader in OTC generics, had faced pressure over the past few years from industry-wide price erosion, challenges in its animal health business, and a reduction in FDA approvals. In addition, Perrigo sold its Animal Health business for $185 million.

  • When Deal Genius Fails: Hard Lessons From 3G to SoftBank
    Bloomberg

    When Deal Genius Fails: Hard Lessons From 3G to SoftBank

    (Bloomberg) -- They’re the big dogs of modern mergers and acquisitions—rapacious dealmakers that have devoured mighty corporations, bankrolled young disrupters and upended entire industries. And they’re not looking so tough anymore.Since 2014, when the latest wave of mergers and acquisitions began to build, three names have inspired fear and envy in the M&A world. In doing so, each has been totemic of a particular vogue in the capital markets:3G Capital, the Brazilian investment firm that has picked off some of America’s most famous brands and aggressively squeezed out costs and jobs Valeant Pharmaceuticals, the ill-fated Canadian company that gobbled up drugmakers, drove up prices and fueled outrage over high prescription costs And SoftBank, the big-dreaming—and big-spending—Japanese conglomerate that has backed the likes of Uber and WeWork and remains one of the most powerful forces in Silicon ValleyFrom the start, the three M&A powerhouses adopted wildly different strategies. But for any investor, the similarities deserve attention. Wall Street believed them and their many imitators to be exceptional. Turns out, they weren’t, and aren’t.(4)That’s worth remembering at a moment when the financial world is struggling to come to grips with the yawning gap between what the pros think companies are worth and what those companies actually fetch on public markets. (See WeWork’s botched initial public offering).Not long ago, 3G, co-founded by billionaire Jorge Paulo Lemann, seemed unstoppable. Lemann became a global name by cobbling together the world’s biggest beermaker, Anheuser-Busch InBev; picking up brands like Burger King and Tim Hortons; and driving the 2015 merger between Kraft and Heinz to create one of world’s largest food companies.3G has since stumbled—hard. Mixing Kraft and Heinz turned out to be a disastrous idea, and not just for those two companies.The investment firm’s usual combine-and-cut formula failed miserably at Kraft Heinz. Since Lemann teamed up with none other than Warren Buffett to do the deal, sales and profits have tanked. 3G’s dream of turning Kraft Heinz into the savior of Big Food ended when Unilever rebuffed its $143 billion takeover offer in 2017. This February, Kraft Heinz took a staggering $15.4 billion writedown. The company’s stock has plunged more than 70% from its peak, helping to drag down rivals like Kellogg, Campbell Soup and General Mills.Former management consultant Michael Pearson had a similarly radical idea at Valeant: that drugmakers like itself had no business actually making drugs.Instead, it would borrow money to acquire rivals, dramatically increase the price of their treatments and fire almost everyone. Rinse, repeat. Valeant’s ambition peaked in 2014 when it teamed up with activist investor Bill Ackman to mount an audacious $54 billion takeover offer for Allergan, the maker of Botox.The bid was spurned, but Ackman and Pearson were undimmed and, as if to prove their theory, took the company on a buying spree that included gastrointestinal drugmaker Salix ($11.1 billion) and Sprout, a developer of female libido stimulants ($1 billion). For a while investors approved, sending Valeant’s market value to $90 billion in August 2015. Then things went spectacularly wrong.Accounting irregularities, mounting debts and political angst over surging drug prices destroyed not only the Valeant dream, but those of the entire specialty pharmaceuticals industry. Among those that followed Valeant to that 2015 peak, Perrigo, Endo International, and Mallinckrodt have since lost, respectively, 74%, 96%, and 98% of their market values. For its part, Valeant is 93% lower, with a new management, board and shareholder base, and has renamed itself Bausch Health.There is no nice way to bring SoftBank into this part of the story.By almost any conceivable measure, it is having a diabolical 2019. The quixotic Masayoshi Son, a startup kingmaker of undoubted brilliance, has staked SoftBank’s billions—and its reputation—on three companies: Uber, the ride-hailing app which has lost about a third of its value, or $19 billion, since its May IPO; Slack, a messaging platform which debuted in June and is down 35% from where it ended its first trading day; and WeWork.(5)The scale of these blowups, so starkly at odds with SoftBank’s recent esteemed status, has dislocated the U.S. IPO markets as investors and would-be public companies look skeptically at one another across a widening gulf of value perception.In hindsight, the impermanence of the three dealmakers’ strategies is easy to skewer. But the success of 3G and Valeant was fueled by some of the most well-known names in finance. SoftBank, meanwhile, tapped entire nations to bankroll its ambitions of creating a future of robot-human harmony.These failures could end up restricting Son’s access to future funding, but it’s unlikely to diminish his vision for what he has said is a 300-year plan to grow the company he started 38 years ago.Nor, probably, will it dampen his enthusiasm for what he has called the gold rush of investing in nascent technology. “It’s just a money thing. It’s not important, it’s just a process. What is more important is humans’ happiness. How do we help ourselves, humans, become happier?” Son said in 2017, calling himself a “super optimist.” “There’s always a solution.”What’s more likely is the end of the burgeoning trend of taking loss-making companies public in the hope the future will come to them. Perhaps, too, some doubt will attach itself to the idea that pumping a young business with money and expecting it to succeed isn’t an idea of wheel-inventing novelty.Either way, there will be something else to worship soon enough. There always is.(1) Another area of commonality is a tolerance for bad corporate governance. In the case of Kraft Heinz and (to be very charitable) Valeant, there was sloppy accounting. For SoftBank, it was willing to put up with the various untraditional practices of Travis Kalanick and Adam Neumann.(2) I can’t add anything revelatory to the mass that has been written about SoftBank and WeWork, the fact that it valued it at $47 billion, whether or not Messrs. Son and Neumann met for 10, 30, or 60 minutes, etc. So I won’t. But it’s hard to feel not a little sad for Adam Neumann. The Disney prince/founder/ex-CEO of WeWork, who just weeks ago was gallantly riding toward his public market destiny, has been banished from the kingdom, leaving a regency of lesser mortals to seize the reins.To contact the author of this story: Ed Hammond in New York at ehammond12@bloomberg.netTo contact the editor responsible for this story: Daniel Hauck at dhauck1@bloomberg.net, David GillenBen ScentFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Perrigo® Hosts 175 West Michigan Students for Manufacturing Week Celebration
    PR Newswire

    Perrigo® Hosts 175 West Michigan Students for Manufacturing Week Celebration

    Students from Seven Area High Schools Spent the Day at Perrigo's Allegan, Mich. Plants: Manager from Valued Customer, Walmart, Demonstrated Perrigo Products' Retail Journey ALLEGAN, Mich. , Oct. 3, 2019 ...

  • Perrigo Announces the Relaunch of the AB Rated Generic Version of Transderm Scop® 1.5 MG
    PR Newswire

    Perrigo Announces the Relaunch of the AB Rated Generic Version of Transderm Scop® 1.5 MG

    TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and therapeutic equivalents for the 12 months ending August 2019 were approximately $147 million. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com.

  • 5 Health Care Stocks Held By Gurus
    GuruFocus.com

    5 Health Care Stocks Held By Gurus

    Bausch Health Companies tops the list Continue reading...

  • Read This Before Selling Perrigo Company plc (NYSE:PRGO) Shares
    Simply Wall St.

    Read This Before Selling Perrigo Company plc (NYSE:PRGO) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Generic Drug Stocks Latch Onto Buyout News — Leading To 3-Day Rally
    Investor's Business Daily

    Generic Drug Stocks Latch Onto Buyout News — Leading To 3-Day Rally

    Shares of generic pharmaceutical companies rallied Friday after Perrigo announced its acquisition of GlaxoSmithKline's heartburn treatment, a medicine known as Prevacid 24-hour.

  • Perrigo To Present At Upcoming Investor Conferences
    PR Newswire

    Perrigo To Present At Upcoming Investor Conferences

    TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host one-on-one meetings at the Barclay's Global Consumer Staples Conference on September 5, 2019 in Boston. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray
    PR Newswire

    Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Barrons.com

    The 6 Worst Health-Care Stocks So Far This Month

    For health care investors this August, things could have been worse. But the past few weeks have been downright disastrous for some stocks.

  • PetIQ, Inc. (PETQ) Q2 2019 Earnings Call Transcript
    Motley Fool

    PetIQ, Inc. (PETQ) Q2 2019 Earnings Call Transcript

    PETQ earnings call for the period ending June, 30, 2019.

  • Perrigo (PRGO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Perrigo (PRGO) Q2 2019 Earnings Call Transcript

    PRGO earnings call for the period ending June 30, 2019.

  • TheStreet.com

    Perrigo Beats Second-Quarter Estimates but Stock Tumbles

    Perrigo is falling despite beating Wall Street's second-quarter earnings and revenue expectations.